936361-35-2

Usage

Uses

Used in Pharmaceutical Development:
3-(pyridin-4-yl)-1H-indazol-5-amine is used as a building block for the synthesis of pharmaceutical drugs and biologically active compounds. Its unique structure, including the pyridin-4-yl and amine groups, provides opportunities for further chemical modifications and the development of new drug candidates with potential therapeutic applications.
Used in Medicinal Chemistry Research:
3-(pyridin-4-yl)-1H-indazol-5-amine is used as a research tool in medicinal chemistry to study the structure-activity relationships of indazole-based compounds. By investigating the effects of different substitutions and modifications on the compound's properties, researchers can gain insights into the design of more effective and selective drug molecules.
Used in Drug Discovery:
3-(pyridin-4-yl)-1H-indazol-5-amine is used as a starting material in drug discovery efforts, where it can be further optimized to develop new therapeutic agents with improved potency, selectivity, and pharmacokinetic properties. Its potential applications may include the treatment of various diseases and disorders, depending on the specific modifications and target interactions.

InChI:InChI=1/C12H10N4/c13-9-1-2-11-10(7-9)12(16-15-11)8-3-5-14-6-4-8/h1-7H,13H2,(H,15,16)

Upstream product

• 478837-59-1 3-bromo-1H-indazol-5-amine 
• 1692-15-5 4-pyridylboronic acid 
• 5401-94-5 5-nitroindazole 
• 67400-25-3 3-bromo-5-nitro-1H-indazole 

Relevant academic research and scientific papers

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

INDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Selective Inhibitors of G2019S-LRRK2 Kinase Activity

Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson's disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.

FUSED TETRAZOLES AS LRRK2 INHIBITORS

The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Efficient synthesis of 3-aryl-1H-indazol-5-amine by Pd-catalyzed Suzuki-Miyaura cross-coupling reaction under microwave-assisted conditions

Various 3-aryl-1H-indazol-5-amine derivatives were synthesized by Pd-catalyzed Suzuki-Miyaura cross-coupling reaction of (NH) free 3-bromo-indazol-5-amine with arylboronic acids under microwave-assisted conditions. The coupling reaction can be carried out under the conditions with dioxane/H2O as solvent, Pd(OAc)2 and RuPhos as catalyst system, and K3PO4 as a base in good to excellent yields.